PDF(Pubmed)
Abstract：
UNASSIGNED: The role of fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in early breast cancer treated with preoperative systemic therapy (PST) is not yet established in clinical practice. PET parameters have aroused great interest in the recent years, as non-invasive dynamic biological markers for predicting response to PST.
UNASSIGNED: In this retrospective study, we included 141 patients with stage II-III breast cancer who underwent surgery after PST. Using ROC analysis, we set optimal cutoff of FDG-PET/CT parameters predictive for pathological complete response (pCR). We investigated the correlation between FDG-PET/CT parameters and pCR, median disease-free survival (DFS), and median overall survival (mOS).
UNASSIGNED: At multivariable analysis, baseline SUVmax (high vs low: OR 9.00, CI 1.85 - 61.9, p=0.012) and Delta SUVmax (high vs low: OR 9.64, CI 1.84, 69.2, p=0.012) were significantly associated with pCR rates. Interestingly, we found that a combined analysis of the metabolic parameter Delta SUVmax with the volume-based parameter Delta MTV, may help to identify patients with pCR, especially in the subgroup of hormone receptor positive breast cancer. Delta SUVmax was also an independent predictive marker for both mDFS (high vs low: HR 0.17, 95%CI 0.05-0.58, p=0.004) and mOS (high vs. low: HR 0.19, 95%CI 0.04-0.95, p=0.029).
UNASSIGNED: Our results suggest that Delta SUVmax may predict survival of early BC patients treated with PST.
UNASSIGNED: In this retrospective study, we included 141 patients with stage II-III breast cancer who underwent surgery after PST. Using ROC analysis, we set optimal cutoff of FDG-PET/CT parameters predictive for pathological complete response (pCR). We investigated the correlation between FDG-PET/CT parameters and pCR, median disease-free survival (DFS), and median overall survival (mOS).
UNASSIGNED: At multivariable analysis, baseline SUVmax (high vs low: OR 9.00, CI 1.85 - 61.9, p=0.012) and Delta SUVmax (high vs low: OR 9.64, CI 1.84, 69.2, p=0.012) were significantly associated with pCR rates. Interestingly, we found that a combined analysis of the metabolic parameter Delta SUVmax with the volume-based parameter Delta MTV, may help to identify patients with pCR, especially in the subgroup of hormone receptor positive breast cancer. Delta SUVmax was also an independent predictive marker for both mDFS (high vs low: HR 0.17, 95%CI 0.05-0.58, p=0.004) and mOS (high vs. low: HR 0.19, 95%CI 0.04-0.95, p=0.029).
UNASSIGNED: Our results suggest that Delta SUVmax may predict survival of early BC patients treated with PST.
摘要：
UNASSIGNED：在临床实践中，氟脱氧葡萄糖（FDG）正电子发射断层扫描/计算机断层扫描（PET/CT）在术前全身治疗（PST）治疗的早期乳腺癌中的作用尚未确定。PET参数近年来引起了人们极大的兴趣,作为预测对PST反应的非侵入性动态生物标志物。
未经评估：在这项回顾性研究中，我们纳入了141例II-III期乳腺癌患者,他们在PST后接受了手术.使用ROC分析，我们设定了预测病理完全缓解（pCR）的FDG-PET/CT参数的最佳截止值。我们研究了FDG-PET/CT参数与pCR之间的相关性，中位无病生存期（DFS），和中位总生存期（mOS）。
未经证实：在多变量分析中，基线SUVmax(高vs低:OR9.00,CI1.85-61.9,p=0.012)和DeltaSUVmax(高vs低:OR9.64,CI1.84,69.2,p=0.012)与pCR率显著相关。有趣的是,我们发现，将代谢参数DeltaSUVmax与基于体积的参数DeltaMTV进行组合分析，可能有助于识别pCR患者，尤其是在激素受体阳性乳腺癌亚组中。DeltaSUVmax也是mDFS（高vs低：HR0.17，95CI0.05-0.58，p=0.004）和mOS（高vs.低：HR0.19，95CI0.04-0.95，p=0.029）。
UNASSIGNED：我们的结果表明DeltaSUVmax可以预测接受PST治疗的早期BC患者的生存。
未经评估：在这项回顾性研究中，我们纳入了141例II-III期乳腺癌患者,他们在PST后接受了手术.使用ROC分析，我们设定了预测病理完全缓解（pCR）的FDG-PET/CT参数的最佳截止值。我们研究了FDG-PET/CT参数与pCR之间的相关性，中位无病生存期（DFS），和中位总生存期（mOS）。
未经证实：在多变量分析中，基线SUVmax(高vs低:OR9.00,CI1.85-61.9,p=0.012)和DeltaSUVmax(高vs低:OR9.64,CI1.84,69.2,p=0.012)与pCR率显著相关。有趣的是,我们发现，将代谢参数DeltaSUVmax与基于体积的参数DeltaMTV进行组合分析，可能有助于识别pCR患者，尤其是在激素受体阳性乳腺癌亚组中。DeltaSUVmax也是mDFS（高vs低：HR0.17，95CI0.05-0.58，p=0.004）和mOS（高vs.低：HR0.19，95CI0.04-0.95，p=0.029）。
UNASSIGNED：我们的结果表明DeltaSUVmax可以预测接受PST治疗的早期BC患者的生存。
